| Pharmaceutical active ingredients: |
| Dihydroergotamine Mesylate |
| Available forms, composition and doses of Ergovasan Retard: |
| Capsules, Retard; Oral; Dihydroergotamine Mesylate 2.5 mgCapsules, Retard; Oral; Dihydroergotamine Mesylate 5 mg |
| Ergovasan Retard medical category: |
| Human:Antimigraine preparationsSympatholytic (adrenergic blocking) agents |
| Indications and usages, anatomical therapeutic chemical and diseases classification codes: |
| N02CA01 - Dihydroergotamine |
| Pharmaceutical companies: manufacturers, researchers, developers, local distributors and suppliers: |
| FujisawaKlinge Pharma |
| Trade name |
Active ingredients |
Pharmaceutical company |
|
Ergont Retard | Dihydroergotamine Mesylate | Desitin Arzneimittel |
| Ergotam | Dihydroergotamine Mesylate | CT-Arzneimittel |
| Ergotonin | Dihydroergotamine Mesylate | G. Streuli |
| Ergotonine | Dihydroergotamine Mesylate | G. Streuli |
| Ergovasan | Dihydroergotamine Mesylate | Fujisawa; Klinge Pharma |
| Ikaran | Dihydroergotamine Mesylate | Pierre Fabre; Formenti Farmaceutici; Nycomed; Robapharm |
| Ikaran LP | Dihydroergotamine Mesylate | Pierre Fabre |
| Ikaran Retard | Dihydroergotamine Mesylate | Pierre Fabre; Robapharm |
| Migranal | Dihydroergotamine Mesylate | Novartis; Sterimax; Valeant Pharmaceuticals |
| Migranil Injections | Dihydroergotamine Mesylate | Inga Laboratories |